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Abstract
Few controlled laboratory studies have examined the negative effects non-steroidal anti-inflammatory
drugs can have on fluid–electrolyte balance during exercise. Our objective was to determine whether a
24-h naproxen dose negatively affected hydration and electrolyte measures before, during, and 3 h after
90 min of cycling in a hot or ambient environment. Using a double blind, randomized and counterbal-
anced cross-over design, 11 volunteers (six male, five female) completed four trials, with conditions as
follows: (1) placebo and ambient, (2) placebo and heat, (3) naproxen and ambient, and (4) naproxen
and heat. We found no statistically significant differences among experimental conditions for any
dependent measures. Though not statistically significant, mean fluid volume was higher and urine vol-
ume was lower during naproxen trials compared with placebos. Mean aggregate plasma sodium was
<135 mmol/L at all time points and did not significantly change over time. Overall plasma potassium
significantly increased pre- (3.9± 0.4) to post-exercise (4.2± 0.4 mmol/L, p = 0.02). In conclusion, an
acute naproxen dose did not significantly alter hydration–electrolyte balance. The trend for naproxen
to increase fluid volume and decrease urine volume suggests the start of fluid retention, which should
concern individuals at risk for hyponatremia or with pre-existing cardiovascular conditions.
Key words: NSAID, fluid volume, urine volume, plasma sodium, plasma potassium
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) include a variety of prescription and non-prescription
medications including aspirin, ibuprofen, and naproxen. An individual drug’s effectiveness and
side effects are dependent on the medication’s chemical makeup and selectivity toward inhibiting
cyclooxygenase (COX). Two COX derivatives (−1 and −2) are found in humans. Inherently located
in most tissues, COX-1 is responsible for regulating gastric mucosa secretions, platelet aggregation
(clotting), and renal blood flow (Constanti et al. 1998). COX-2, present in very small amounts natu-
rally, is upregulated locally by inflammatory mediators (e.g., cytokines) and facilitates inflammation,
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pain, and fever (Constanti et al. 1998). Anti-inflammatory and analgesic NSAID effects occur by pre-
venting COX from catalyzing the conversion of arachidonic acid (fatty acid released from cell mem-
branes during injury/inflammation) to prostaglandin (PG). Numerous PG subsets are responsible
for not only promoting pain and inflammation, but also maintaining blood pressure (BP), plasma vol-
ume, and renal function. Less imperative in normal healthy individuals, PGs are critical in maintain-
ing homeostasis during altered cardiovascular states (e.g., hypotension) or altered fluid regulation
(e.g., hypovolemia and sodium imbalance) (Garella and Matarese 1984)—common conditions experi-
enced during physical activity. Inhibiting PGs can perpetuate altered cardiovascular and renal func-
tion, potentially leading to serious fluid and electrolyte imbalances (e.g., hyponatremia and
hypertension) or even acute renal failure (Garella and Matarese 1984; Rosner and Kirven 2007).
Existing literature on NSAIDs and fluid regulation during physical activity primarily includes observa-
tional and retrospective cases of exertional hyponatremia (plasma sodium concentration (P[Na+])
< 135 mmol/L) (Almond et al. 2005; Wharam et al. 2006; Rosner and Kirven 2007). NSAIDs are
thought to potentiate hyponatremia by decreasing urine production and increasing water retention,
which dilutes P[Na+] (Cheng and Harris 2005). To our knowledge, there is one controlled study exam-
ining this relationship, which found that a 600 mg dose of ibuprofen before and a 1200 mg dose during a
160-km race (with a temperature range 9–30 °C) did not significantly alter plasma electrolytes (Dumke
et al. 2007). Controlled laboratory studies examining NSAID effects on fluid–electrolyte balance during
exercise are lacking. Thus, as part of a larger study, we sought to determine acute dose effects of a com-
monly used over-the-counter NSAID, naproxen, on fluid and electrolyte measures during moderate-
intensity endurance exercise in a hot or ambient environment. We hypothesized naproxen would
increase hydration (i.e., euhydration or hyperhydration) compared with placebo controls. We also
hypothesized naproxen would significantly decrease P[Na+] compared with placebo controls.
Methods
Participants
Seventeen participants (12 male, five female) began the study. Two participants withdrew from the
study due to the exercise intensity and pills, three due to the time commitment, and one due to a
non-study-related injury. Our final sample size was 11 (six male, five female). Prior to participation,
participants read and signed an informed consent form approved by the University of South
Carolina Institutional Review Board.
Potential participants were recruited from the University of South Carolina and the local Columbia,
South Carolina community via posted flyers and word of mouth. To be considered for the study,
participants completed a health and injury history questionnaire and were accepted if they were free
of cardiovascular, respiratory, metabolic, musculoskeletal, fluid–electrolyte, gastrointestinal, and
swallowing disorders. Potential participants then completed a graded cycling V˙O2max test to deter-
mine qualification as moderately trained (V˙O2max 32–40 mL/(kg·min)) and familiarize participants
with the stationary cycle. The health and injury questionnaire also included information on current
prescription and non-prescription medication use, and females answered questions about their men-
strual cycle and birth control. Baseline anthropometric measures included height (self-reported),
weight, and body fat percentage (measured using a Tanita SC-331S Body Composition Monitor,
Tanita Co., Tokyo, Japan).
Experimental design and procedures
A schematic of the experimental procedures is shown in Figure 1. Using a double-blind, randomized
and counterbalanced, cross-over design, we evaluated the effect of naproxen or placebo in a hot or ambi-
ent environment. Participants completed trials under the following four experimental conditions:
Emerson et al.
FACETS | 2017 | 2: 819–832 | DOI: 10.1139/facets-2017-0042 820
facetsjournal.com
FA
CE
TS
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.fa
ce
tsj
ou
rna
l.c
om
 by
 19
5.1
95
.4.
18
0 o
n 0
6/1
1/1
9
(1) placebo and ambient (Control), (2) placebo and heat (Heat), (3) naproxen and ambient (Npx), and
(4) naproxen and heat (NpxHeat). A minimum of 7 d separated each trial. A 24-h dose (three capsules)
of placebo (cellulose) or naproxen (220 mg naproxen sodium per dose) was given to participants with
instructions to take one capsule at 16, 8, and 0 h prior to data collection. Instructions to take each pill
(i.e., timing, with at least 8 oz of fluid and not with food) were based on Aleve® manufacturer directions.
To blind participants and primary investigators to naproxen or placebo trials, a local pharmacy com-
pounded pills to appear the same. A research assistant prepared coded envelopes containing pills for
each trial and randomly assigned participants to an experimental order prior to data collection.
To control for the effects of dietary and physical activity pre-data collection, participants tracked diet
and physical activity for 3 d prior and 1 d after data collection using the online nutrition software
FoodProdigy™ (ESHA Research, Salem, Oregon, USA). Participants were instructed to refrain from
intense, vigorous exercise 48 h prior to data collection (Peters et al. 2000). Twenty-four hours prior,
participants were provided written and verbal instructions for taking two pills (placebo or naproxen),
to consume a small meal prior to reporting to the laboratory, consume fluids to promote euhydration,
refrain from all physical activity, and attempt to sleep a “normal” amount. Using the diet and physical
activity habits from the 24 h prior to the first trial, participants were instructed to mimic the same diet
and physical activity habits 24 h prior to each subsequent trial. Participants were also instructed to not
take any other analgesic or anti-inflammatory medications during the course of the study.
Upon arrival to the laboratory for data collection and before taking the third pill, participants were
verbally asked if they took their previous two pills. Baseline hydration, electrolyte, and cardiovascular mea-
sures were assessed prior to participants cycling for 90 min in either a hot (temperature = 35.7± 1.3 °C,
relative humidity (RH) = 53.2%± 3.2%) or ambient (temperature = 22.7± 1.8 °C, RH = 52.4%± 5.5%)
environment. Immediately following exercise, participants were weighed, provided a urine sample, and
had blood collected. Participants then rested for 3 h in a semi-reclined/seated position in an ambient
environment (23 °C, 56% RH) where they were allowed to consume water ad libitum and given a snack.
Due to the larger study, snacks were sugar free and quantity for each trial was based on baseline body mass
(BM). Three hours after exercise, hydration, electrolyte, and cardiovascular measures were again assessed.
Cycling protocol
The 90-min cycling protocol was completed on a stationary bike (Monark Ergomedic 828E, Monark
Exercise AB, Vansbro, Sweden). Prior to a 3-min warm up, participants were provided their target
Information session 3 d—1 d prior todata collection 
Data collection (4 trials)
- Informed consent 
- Health information
- Cycling VO2max test
- Experimental 
condition 
assignments
- 3 d
- Begin diet and 
physical activity log
- No vigorous 
exercise
- 1 d
- Written and verbal 
take home 
instructions
- 2 pills
- Continuous HR
- 3.5 mL/kg 
water every 15 
min
Arrive to lab 90 min cycling Post-exercise
- Confirm 2 pills 
taken
- Give 3rd pill
- Baseline
- Blood
- Urine
- BM
- HR and BP
- Blood
- Urine
- BM
- BP and HR
3 h post-
exercise
- Water ad libitum
- Post
- Blood
- Urine
- BM
- BP and HR
Fig. 1. Schematic of the experimental procedures. Blood measures include plasma osmolality, plasma sodium concentration, and plasma potassium concentra-
tion. Urine measures include urine osmolality and urine specific gravity. BM, body mass; BP, blood pressure; HR, heart rate.
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heart rate (HR), equivalent to 70% V˙O2max, to maintain during 80 min of steady-state cycling.
Participants were instructed to reach the HR by the end of the 3-min warm up. At the end of
80 min, participants performed 10 min at maximum effort, with each participant given verbal encour-
agement by research assistants. The protocol concluded with a 5-min cool down.
Hydration and electrolyte measures
Hydration measures included plasma osmolality (Posm), urine osmolality (Uosm), urine specific
gravity (Usg), and percent change in body mass (%BM). Participants were required to be euhydrated
prior to beginning data collection (Posm ≤ 290 mOsm/L, Uosm < 700 mOsm/L, Usg ≤ 1.020, and
(or) %BM < 1%) (Sawka et al. 2007). Immediate hydration status was assessed using Usg. Further
hydration analysis was conducted using Posm, Uosm, and %BM.
A research assistant collected blood from an antecubital vein into 6 mL lithium heparin vacutainer
tubes pre-, immediately post-, and 3 h post-exercise. Tubes were inverted several times to mix and
immediately placed on ice. Samples were centrifuged at 3000 rpm for 15 min. Plasma was pipetted
into microtubes and stored at −20 °C until analysis. Osmolality was measured using freeze point
depression (using a Multi-sample Osmometer model 2020, Advanced Instruments, Norwood,
Massachusetts, USA). To determine changes in P[Na+] and plasma potassium concentration
(P[K+]), we used ion-selective electrodes (using an EasyLyte® Na/K electrolyte analyzer model
REF 2277, Medica, Bedford, Massachusetts, USA). Normal P[Na+] was defined as >135 mmol/L
(Rosner and Kirven 2007) and normal P[K+]< 5 mmol/L (Clausen 2010).
Urine was obtained pre-, immediately post-, and 3 h post-exercise. Participants urinated a small
amount before placing the specimen cup in midstream to collect a minimum of 1 oz of urine.
A handheld clinical refractometer (model REF 312, Atago Company Ltd., Tokyo, Japan) was used
to measure Usg. Urine aliquots were stored in microtubes at − 20 °C until osmolality analysis. All
urine produced after pre-hydration measures were collected into Uvol containers and urine cups
(for Usg and Uosm measures). Total urine volume (Uvol) produced over the trial was measured
using a graduated cylinder.
Pre-, immediately post-, and 3 h post-exercise BM was measured using a body composition analyzer
(Tanita SC-331S Body Composition Monitor, Tanita Co., Tokyo, Japan). Participants dressed in
shorts and a t-shirt and voided urine before stepping on the scale. Immediately post-exercise partici-
pants toweled off sweat before weighing. Participants were then allowed to change clothes and
instructed to return with their “wet” clothes to be weighed. Differences in “wet” versus “dry” clothes’
weight (measured at another time) were used to adjust BM for sweat loss. We calculated sweat rate
using the formula: (pre-activity BM − post-activity BM + fluid volume consumed − urine volume)/
exercise time (Casa et al. 2000).
Fluid volume measures
To maintain hydration during exercise, participants were instructed to drink 3.5 mL/kg of water
every 15 min. Participants were allowed to consume more than required if they desired. At the end
of exercise, researchers measured total fluid volume (Fvol) consumed. During the 3-h rest period,
participants consumed water ad libitum and researchers measured Fvol consumed during rest.
Cardiovascular measures
To ensure that participants maintained the target HR and remained at safe limits during exercise, HR
was continuously monitored using Polar HR monitors (Polar Electro Inc., Lake Success, New York,
USA). BP was measured using a standard sphygmomanometer and stethoscope. Measures were taken
Emerson et al.
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by a research assistant and recorded every 15 min during exercise. Pre-, immediately post-, and 3 h
post-exercise HR and BP were assessed.
Statistical analysis
IBM SPSS Statistics (version XXII; IBM Corporation, Armonk, New York, USA) was used for all
analyses. Descriptive statistics (mean and standard deviations) for all dependent variables were calcu-
lated. A one-way ANOVA was used to determine demographic differences between genders (e.g., age,
height, weight). A 3 (time) × 4 (condition) repeated measures ANOVA determined differences for
plasma, urine, %BM, HR, and BP. Greenhouse–Geisser corrections were used for P[Na+], BP, and
HR because these variables violated sphericity. Post hoc analysis was conducted for significant main
effects using Bonferroni corrections. We used a one-way ANOVA to determine differences among
conditions and between genders for Fvol consumed during exercise, total Fvol, and Uvol. To control
for BM, Fvol was corrected to mL/kg and a one-way ANOVA was used to determined differences
among conditions and between genders. Paired sample t tests determined differences in sweat rate
and Fvol during exercise. Using G*Power (version 3.1.9.2, Heinrich Heine University, Dusseldorf,
Germany) (Faul et al. 2007), post hoc power calculation with means and variances for Usg and
Uosm indicated that statistical power was 0.9. Significance level was set at p< 0.05 for all analyses.
Results
No significant differences were found between genders for age (27.8± 5.7 years), weight (79.1± 17.9 kg),
V˙O2max (41.4 ± 5.7 mL/kg/min), sweat rate (0.9 ± 0.3 L/h), baseline resting HR (52.6 ± 6.6 bpm),
baseline resting systolic (115.6 ± 18.7 mm Hg), and diastolic BP (80.4 ± 6.9 mm Hg). Diet logs
indicated no significant differences for total calories, fat, carbohydrate, sodium, and protein intake
among conditions. On average, male daily sodium intake was significantly higher than that of females
(2.7± 0.3 vs. 2.0± 0.2 g, F[1,20] = 4.953, p = 0.038). Physical activity level 24 h prior to data collec-
tion was not significantly different among conditions and remained low to sedentary. Due to contami-
nated samples, the final sample size for Posm, P[Na+], and P[K+] varied among conditions
(Control = 5, Npx = 3–4, Heat = 4, and NpxHeat = 3–4).
Hydration
Hydration measures for each experimental condition are presented in Table 1. No significant
differences were found in hydration measures among conditions at any time point. All participants
began trials euhydrated. Significant main effects for Posm (F[2,26] = 5.165, p = 0.013), Uosm
(F[2,66] = 17.257, p < 0.001), and Usg (F[2,80] = 10.081, p < 0.001) occurred for time. Pairwise
comparisons indicated that participants became more hydrated pre- to 3 h post-exercise (Table 1).
All conditions maintained an average BM loss < 1%.
Though not significantly different, mean Uvol was lower in the naproxen trials versus the placebo trial
and during heat trials versus ambient trials (Table 2). There was no significant difference in Uvol
between genders. Neither Fvol during exercise nor total Fvol was significantly different among condi-
tions. Participants tended to consume more fluid during exercise in hot conditions versus ambient
conditions (Table 2). Mean Fvol during exercise and overall was higher in both naproxen trials com-
pared with placebo trials. This trend continued when corrected for BM. Participants’ mean Fvol
during 90 minutes of cycling (1.5± 0.7 L) was significantly higher than their sweat rate (0.9± 0.3 L/h,
t(10) = −8.369, p = 0.013). Compared with females, males consumed significantly greater Fvol during
exercise (1.1 ± 0.5 and 1.7 ± 0.7 L, respectively, F[1,42] = 10.996, p = 0.002) and total Fvol was also
higher (1.7± 0.7 and 2.5± 1.3, respectively, F[1,41] = 6.854, p = 0.012). During the NpxHeat trial, males
consumed significantly more Fvol during exercise than females (2.0± 0.6 vs. 1.3± 0.5 L, F[1,9] = 5.337,
p = 0.046). When corrected for BM, Fvol in males overall and during the NpxHeat trial was not
Emerson et al.
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Table 1. Hydration measures for the experimental conditions (M± SD) before exercise (pre), immediately
following exercise (post), 3 h after exercise (3 h post), and between one measurement time and another.
Aggregate Control Npx Heat NpxHeat
Plasma osmolality (mOsm/L)
Pre 286.6± 6.4a 285.8± 5.3 288.8± 4.8 285.5± 10.1 287.8± 6.6
Post 284.8± 6.7 288.2± 6.6 281.9± 3.9 285.9± 10.6 283.8± 4.9
3 h post 282.4± 5.9 286.4± 3.3 277.4± 6.6 283.6± 6.9 281.1± 4.9
Urine osmolality (mOsm/L)b
Pre 399.5± 172.1c 441.6± 187.5 431.8± 193.5 341.4± 131.7 389.9± 183.4
Post 277.3± 236.0 246.8± 223.7 244.2± 184.1 233.1± 213.9 390.2± 310.0
3 h post 176.2± 132.9 192.4± 107.8 185.6± 130.4 201.3± 173.0 122.7± 113.3
Urine specific gravity
Pre 1.012± 0.005 1.013± 0.005 1.014± 0.006 1.011± 0.004 1.012± 0.004
Post 1.011± 0.008 1.010± 0.007 1.010± 0.008 1.010± 0.008 1.013± 0.009
3 h post 1.007± 0.006d 1.007± 0.005 1.007± 0.006 1.007± 0.006 1.007± 0.007
Body mass change (%)
Pre–post −0.1± 0.8 0.1 ± 0.8 −0.3± 1.1 0.0± 0.6 −0.1± 0.8
Pre–3 h post −0.4± 0.9 −0.6± 0.4 −0.1± 0.6 −0.5± 0.6 −0.5± 0.9
Post–3 h post −0.3± 0.7 −0.5± 0.8 0.0± 1.3 −0.4± 0.5 −0.0± 0.6
Note: Npx, naproxen.
aSignificantly higher than 3 h post- (p = 0.01) exercise.
bSignificant main effect across time for all conditions (p< 0.001).
cSignificantly higher than immediately post- (p = 0.003) and 3 h post- (p< 0.001) exercise.
dSignificantly lower than pre- (p< 0.001) and immediately post- (p = 0.03) exercise.
Table 2. Fluid and urine volume for the experimental conditions (M± SD).
Aggregate Control Npx Heat NpxHeat
Urine volume (mL)
Total 1012.9± 519.1 1157.3± 681.4 1075.3± 572.3 982.6± 508.6 836.6± 214.2
Fluid volume (L)
Exercise 1.5± 0.7 1.1± 0.4 1.4± 0.9 1.6± 0.6 1.7± 0.7
Total 2.1± 1.1 1.7± 0.6 2.1± 1.5 2.2± 1.0 2.5± 1.3
Fluid volume (mL/kg)
Exercise 17.8± 6.3 14.2± 4.2 16.8± 8.3 19.6± 4.9 20.4± 5.8
Total 25.9± 10.0 21.5± 6.6 25.5± 13.4 27.3± 8.1 29.5± 10.6
Note: Npx, naproxen. No significant differences among the experimental conditions.
Emerson et al.
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significantly different than in females. During the Npx trial, overall Fvol approached significance
(males = 1.9± 1.0 L and females = 0.9± 0.5 L, F[1,9] = 4.859, p = 0.055) and was different between
genders during exercise with BM corrections (males = 20.7 ± 8.8, females = 12.1 ± 5.0 mL/kg,
p = 0.087).
Electrolytes
Table 3 presents plasma electrolytes by experimental condition. Mean aggregate P[Na+]
was <135 mmol/L pre-, immediately post-, and 3 h post-exercise. No statistically significant
differences were found for P[Na+] among conditions at any time. Mean P[Na+] was highest during
the NpxHeat trials. A significant main effect for P[K+] was found over time (F[2,26] = 4.287,
p = 0.025), increasing pre- to post-exercise and then decreasing after 3 h. No statistically signifi-
cant differences among trials were observed, but both naproxen groups averaged higher P[K+]
than placebo groups immediately post-exercise.
Cardiovascular
A significant main effect for HR occurred over time (mean pre = 66.8 ± 14.3 bpm, immediately
post = 177.4 ± 16.2 bpm, and 3 h post = 65.5 ± 11.8 bpm, F[1.7,67.4] = 1171.1, p < 0.001). No
differences among conditions or between genders were observed. A significant main effect occurred
over time for systolic BP (mean pre = 118.3 ± 1.6 mm Hg, immediately post = 137.4± 2.8 mm Hg,
and 3 h = 116.3± 1.3 mm Hg, F[1.6,63.2] = 58.989, p< 0.001) and diastolic BP (mean pre = 73.2±
10.5 mm Hg, immediately post = 71.7 ± 10.1 mm Hg, and 3 h = 76.9 ± 7.8 mm Hg, F[1.7,65.8] =
5.602, p = 0.008). No significant differences among conditions were observed. A significant main effect
for systolic BP between genders was revealed (F[1.7,70.5] = 6.241, p = 0.005). Post hoc analysis showed
that BP in males was significantly higher than in females at all time points (pre = 122.0 ± 2.0 vs.
113.8 ± 2.2 mm Hg, F[1,42] = 6.281, p = 0.016; immediately post = 146.3 ± 3.1 vs. 126.2 ± 3.5 mm
Hg, F[1,41] = 18.897, p < 0.001; and 3 h post = 119.7 ± 1.5 vs. 111.9 ± 1.7 mm Hg, F[1,42] = 13.11,
p = 0.001; respectively). Male systolic BP was significantly higher than females immediately
post-exercise in the Npx (150.8 ± 19.6 vs. 124.4 ± 5.2 mm Hg, F[1,9] = 8.457, p = 0.017) and
NpxHeat trials (144.2± 16.3 vs. 123.5± 5.5 mm Hg, F[1,8] = 5.808, p = 0.043).
Table 3. Plasma electrolytes for the experimental conditions (M± SD) before exercise (Pre), immediately
following exercise (Post), and 3 h after exercise (3 h post).
Aggregate Control Npx Heat NpxHeat
P[Na+] (mmol/L)
Pre 134.3± 4.6 133.5± 5.7 133.2± 4.5 133.5± 3.2 135.0± 2.9
Post 133.5± 3.2 133.3± 2.9 131.5± 4.8 132.2± 5.6 134.8± 3.9
3 h post 134.3± 3.1 133.1± 1.9 133.5± 0.3 132.9± 4.7 135.3± 2.7
P[K+] (mmol/L)a
Pre 3.9± 0.4 3.9± 0.6 4.1± 0.4 3.9± 0.2 3.6± 0.1
Post 4.2± 0.4 4.2± 0.7 4.4± 0.3 3.9± 0.1 4.2± 0.2
3 h post 3.9± 0.2 3.8± 0.3 3.8± 0.0 4.0± 0.3 3.9± 0.3
Note: P[K+], plasma potassium concentration; P[Na+], plasma sodium concentration; Npx,
naproxen.
aSignificant main effect across time (p = 0.02).
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Discussion
We sought to determine whether naproxen adversely affected hydration and electrolyte balance dur-
ing moderate-intensity endurance cycling in either hot or ambient conditions. Based on previous
research (Cheng and Harris 2005), we hypothesized that NSAIDs would promote fluid retention
through decreased Uvol and renal vasoconstriction, subsequently diluting plasma electrolytes,
increasing hydration status, and increasing BP. Our results did not support our hypotheses, finding
that an acute (24-h) naproxen dose did not significantly affect plasma electrolytes, plasma and urine
hydration indices, or cardiovascular strain compared with placebos. We also report that responses
did not differ between either hot or ambient environmental conditions.
Fluid and electrolyte balance
Naproxen is highly effective at inhibiting renal PGs, resulting in decreased renal blood flow (Garella
and Matarese 1984). Specific renal consequences include decreased glomerular filtration rate,
increased vasopressin, increased sodium retention, and decreased Uvol. Naproxen also suppresses
the renin–angiotensin–aldosterone system, which is responsible for maintaining BP, plasma volume,
and electrolyte balance (Cheng and Harris 2005). Independently or concurrently, naproxen’s effects
cause water retention and vasoconstriction (Cheng and Harris 2005). In extreme cases, cell necrosis,
interstitial nephritis, and renal failure may develop (Garella and Matarese 1984). Milder conse-
quences, although they can also become severe, include electrolyte imbalance, edema, and hyperten-
sion (Cheng and Harris 2005; Rosner and Kirven 2007).
Decreasing Uvol and increasing water retention is what makes NSAIDs a suspected contributor to
hyponatremia. Despite this information, few studies have examined this relationship, with most being
observational studies with conflicting results (Davis et al. 2001; Hsieh et al. 2002; Almond et al. 2005;
Wharam et al. 2006). Ultra-distance triathletes using NSAIDs had significantly lower post-race
P[Na+] compared with non-NSAID users (Wharam et al. 2006). The six participants who experienced
hyponatremia all reported using NSAIDs (Wharam et al. 2006). Of 15 marathon runners hospitalized
with severe hyponatremia, 28.6% used NSAIDs (Davis et al. 2001). In contrast, other observational
studies have found no relationship between NSAIDs and hyponatremia (Hsieh et al. 2002; Almond
et al. 2005; Scotney and Reid 2015). One inherent issue with existing literature is not knowing the
NSAID type or dosage. All NSAIDs inhibit PGs, but their COX selectivity and chemical make-up,
along with an individual person’s unique response, means that each NSAID exerts its effects
differently.
Another contributing factor for developing hyponatremia is an individual consuming hypotonic fluid
in excess of fluid lost through sweat and respiration (Rosner and Kirven 2007). If combined with other
factors that dilute P[Na+], the individual can be at greater risk for hyponatremia. Current recommen-
dations advise matching individual sweat losses rather than drinking in excess or following general-
ized protocols (Casa et al. 2000; Sawka et al. 2007). Calculating sweat rate is relatively simple.
However, lack of knowledge, ability, or resources may prohibit a person from calculating their sweat
rate. Instead, the person may guestimate their fluid intake during endurance activity or determine it
by trial and error. We chose to provide a standardized water protocol, rather than match sweat rates,
and participants were allowed to consume more if desired. In part, using a standardized intake mim-
icked what an individual who does not know their personal water needs may do. Consuming water
volumes exceeding sweat loss during 90 min of cycling did not significantly deplete P[Na+], and there
was no effect from naproxen. The lack of P[Na+] depletion is likely due to the short exercise duration.
Exertional hyponatremia is typically associated with endurance exercise lasting longer than 3 h
(Noakes et al. 2005; Rosner and Kirven 2007), but has also occurred in football (Creamer and
Hagedorn 2008; Blevins and Apel 2014; Stevens 2014). Our cycling session likely did not allow enough
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time to significantly deplete P[Na+]. During the 3-h rest, when participants were allowed to drink
water ad libitum they maintained euhydration and plasma electrolyte balance.
One interesting note is our mean P[Na+] was<135 mmol/L in all conditions and time points except
pre- and 3 h post-exercise in the NpxHeat trials. Plasma sodium< 135 mmol/L without signs or symp-
toms is considered biochemical or asymptomatic hyponatremia (Noakes et al. 2005). Many individuals
do not experience symptoms until P[Na+] decreases below 130 mmol/L, and severe hyponatremia typ-
ically occurs below 120 mmol/L (Sawka et al. 2007). Our participants maintained normal diets, consum-
ing an average 2401.1 ± 759.2 mg of sodium daily. The low P[Na+] can be explained by participants
being instructed to arrive at the laboratory hydrated and by maintaining hydration during the exercise
protocol. Pre-exercise Usg, Uosm, and Posm indicated that our participants were slightly hyperhydrated
and became extremely hyperhydrated (Armstrong et al. 2010) by 3 h post-exercise.
It was also interesting that participants in the NpxHeat trials averaged more fluid consumed and had
the lowest Uvol. The trend for naproxen trial participants to produce less urine while consuming
more fluid suggests that participants were retaining water. We did not see significant decreases in
P[Na+], Posm, or Usg pre- to post-exercise. The low sample size for P[Na+] and Posm makes it diffi-
cult to definitively assess whether fluid was retained during naproxen trials. However, we presume a
portion of water remained in the stomach. Intense exercise, such as with our cycling protocol, slows
gastric emptying, which prevents fluid from being absorbed and (or) used to maintain physiological
processes (Robinson et al. 1995).
In principle, increased Fvol and decreased Uvol should lead to BM gains. No significant differences in
BM were found among our experimental conditions. Both the Npx and NpxHeat trial participants
averaged pre- to post-exercise BM losses, whereas both Control and Heat trial participants showed
a slight increase in BM or no change (Table 1). From immediately post- to 3 h post-exercise, this
trend flipped with Control and Heat trial participants showing more weight loss than Npx and
NpxHeat trial participants. Once exercise ceased, it is possible that gastrointestinal and renal function
returned to normal, promoting gastric emptying and water excretion as necessary to maintain fluid–
electrolyte balance. Support for this explanation is found with the slightly higher Uvol in Control and
Heat treatments. In contrast, the continuation of naproxen’s effects throughout the rest period would
explain the slight weight gain and lower average Posm 3 h post-exercise. This is important to note
considering reported cases of hyponatremia developing hours after activity (Creamer and Hagedorn
2008; Stevens 2014). Sustained water retention combined with continued hypotonic fluid consump-
tion would place the person at even greater risk for diluted P[Na+].
Our participants remained within normal P[K+] levels (<5 mmol/L) (Clausen 2010). Potassium is
tightly regulated by the kidneys because elevated plasma levels may cause cardiac arrhythmias and
death (Clausen 2010). Even during exercise, when plasma levels can quickly spike due to working
muscles releasing or failing to re-uptake potassium (Clausen 2010), the kidneys work efficiently to
clear potassium. However, potassium will stay elevated if renal blood flow is decreased
(Franscesconi et al. 1997). NSAIDs, known to decrease renal blood flow (Garella and Matarese
1984), can induce hyperkalemia (Lafrance and Miller 2012), but little scientific information is avail-
able regarding this association during exercise. The increase in our overall P[K+] mean values are sim-
ilar to those reported in existing literature (Wharam et al. 2006; Dumke et al. 2007; McKenney et al.
2015). Although not significantly different among conditions, the higher means for naproxen
compared with placebos suggest that there could be some effect from the NSAID. Among triathletes,
NSAIDs resulted in significantly higher post-race P[K+] compared with those not using NSAIDs
(Wharam et al. 2006). In contrast, over-the-counter ibuprofen did not significantly affect P[K+] in
ultra-distance runners (Dumke et al. 2007). The type of NSAID was not reported by Wharam et al.
(2006); therefore, it is not possible to make comparisons among specific NSAIDs. However, research
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has established that, compared with no NSAID exposure, the odds for developing hyperkalemia
are higher with the use of naproxen than with ibuprofen (Lafrance and Miller 2012). Using a higher
naproxen dose for a longer duration may induce significant P[K+] changes during exercise.
Cardiovascular
Our results indicate 3–220 mg naproxen doses over 24 h did not significantly affect HR or BP.
Cardiovascular responses often occur concurrently with renal responses, because altering fluid–
electrolyte balance can control plasma volume and BP. Disregarding renal effects, naproxen is less effec-
tive at directly altering the cardiovascular system because naproxen is more COX-2 selective (Botting
2006). Further, naproxen reversibly inhibits platelet aggregation. In comparison, aspirin is more selec-
tive toward COX-1 and irreversibly inhibits platelet aggregation, making aspirin highly effective at
reducing cardiovascular events (i.e., stroke, heart attack) (Patrono et al. 2005). Lack of cardiovascular
effects could be attributed to naproxen itself or to our methodology. By maintaining hydration, we lim-
ited cardiovascular changes that would otherwise be seen with hypohydration. We also limited our par-
ticipants to healthy, young, moderately trained individuals. The same cardiovascular results may not be
seen in different populations (e.g., older, poor physical conditioning, cardiovascular or renal disease).
Gender
The current literature indicates that females are at higher risk for hyponatremia because of smaller
BM, excessive water intake, and longer race times compared with males (Rosner and Kirven 2007).
Though these factors play a role, hormonal differences between genders are also an important consid-
eration. Resting plasma vasopressin varies in females depending on menstrual phase. Vasopressin is
significantly lower than males during the early follicular phase, but not during the luteal phase
(Wenner and Stachenfeld 2012). These variances may help explain why we found differences in
Fvol between genders. Males consumed significantly more fluid than females both during exercise
and overall. Interestingly, males consumed significantly more fluid during exercise in the NpxHeat
trials, and approached significance in the Npx trials, compared with females. Gender differences did
not occur during the Control and Heat trials, and we found no difference in females’ Fvol among con-
ditions. Considering the change in vasopressin during menstrual phases, which we did not account
for, the lack of significant findings among females could be partially explained by hormones.
Thirst is listed as a potential side effect for several NSAIDs, but data are limited for the effect of
NSAIDs on thirst or Fvol during exercise. Among NSAID and non-NSAID users completing an
82 km mountain run, NSAID users consumed significantly more fluid than non-users (Scotney and
Reid 2015). Our results support that naproxen use increases fluid intake in males. We used naproxen
sodium, which is bioequivalent to naproxen except for the rate of absorption. The salt of a given
NSAID is commonly used because it allows the drug to dissolve faster and exert effects earlier.
A 220 mg naproxen sodium dose contains approximately 20 mg of sodium. Not all salts exert the
same effects and 20 mg is relatively low, but 46 mg/L of sodium chloride added to a flavored beverage
significantly increased fluid intake (Wemple et al. 1997). A possible explanation for increased Fvol in
our male participants is that naproxen sodium stimulated thirst. Another mechanism for thirst stimu-
lation is an increase in vasopressin from NSAIDs (Cheng and Harris 2005). Vasopressin is typically
upregulated during dehydration to restore plasma volume, and vasopressin increase is positively
and linearly associated with thirst (Wenner and Stachenfeld 2012). Despite our participants being
euhydrated, if naproxen stimulated vasopressin it could have increased their fluid intake.
We identified no differences between or within genders for HR. BP is generally higher for males than
females (Christou et al. 2005), which is attributed to physical differences, hormones, and vascular
responsiveness (Wenner and Stachenfeld 2012). Male baseline BP was slightly higher than females,
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but not significantly. Naproxen significantly elevated post-exercise male systolic BP compared with
females. This did not occur during Control and Heat trials. The increased Fvol with naproxen in
males could partially explain the higher systolic BP. Ostensibly, males would have a higher plasma
volume, which would increase BP.
Limitations and future research
Measuring aldosterone and vasopressin would provide better insight into how naproxen influences
fluid and electrolyte balance. Measuring plasma naproxen concentration would have been useful to
determine the drug’s concentration 3 h post-exercise. Naproxen has a long half-life compared with
other NSAIDs. Therefore, naproxen is expected to continue exerting effects during the 3-h rest,
whereas other NSAIDs would not. This is important when considering post-activity effects. Our
90-min cycling was likely too short to elicit significant P[Na+] changes, considering most hyponatre-
mia research is in marathon and ultra-distance events. Our sample size for plasma electrolytes and
Posm was low, preventing us from achieving statistical significance among conditions for Posm,
P[Na+], and P[K+]. This also limited our ability to extensively examine cardiovascular effects.
Finally, we did not control for menstrual phase.
Future research is warranted to determine the relationship between NSAID use and hydration–
electrolyte balance during exercise. Because each NSAID is unique, studies should evaluate different
types, dosages (e.g., over-the-counter, prescription), and length of use (e.g., 3 d, 2 weeks).
Evaluating longer endurance exercise periods to deplete plasma electrolytes is an important consider-
ation. Longer exercise bouts, particularly marathon and ultra-distance events, is also important due to
the high NSAID use among these athletes. At the same time, examining shorter exercise periods is rel-
evant considering the potential for electrolyte depletion due to other risk factors such as inadequate
nutrition, excessive hypotonic fluid intake, and (or) excessive sweat sodium loss. Using different
hydration regimens (e.g., metered versus ad libitum), fluid types (e.g., carbohydrate-electrolyte bever-
ages), and hydration statuses (e.g., severe hypohydration) is also merited. Considering the trend of
increased Fvol with naproxen use, evaluating vasopressin and thirst would be interesting. Along these
lines, examining the salts of different NSAID types would provide meaningful information. Finally,
controlled studies evaluating markers of renal function and gender differences, including differences
during menstrual phases, are merited.
Conclusion
A 24-h naproxen dose did not adversely affect hydration, electrolyte, or cardiovascular measures
among healthy, hydrated males and females cycling for 90 min in either hot or ambient conditions.
Although our participants maintained electrolyte balance, their P[Na+] was lower than 135 mmol/L.
Finding higher post-exercise systolic BP with naproxen use in males versus females warrants consid-
eration for potential adverse events during exercise in males with pre-existing hypertension. Further,
we found that naproxen use promoted greater fluid intake in males in ambient and hot environments.
Beginning exercise slightly hyperhydrated and consuming water in excess of the sweat rate during our
90 min exercise time began to show a trend for naproxen use to induce water retention through
decreased Uvol. Together, these results suggest that medical personnel should consider an individual’s
risk factors (i.e., gender, fluid intake, existing renal or cardiovascular conditions) when recom-
mending naproxen use during exercise.
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